Evidence map›Paper›PMID 42006192›Full record

ArticleGastro hep advances2026

Sequential Fibrosis-4 Index and Mac-2 Binding Protein Glycosylation Isomer Combination Improve Detection of Advanced Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Multicenter Study.

Asahiro Morishita, Yoshihiro Kamada, Yoshio Sumida, Taeang Arai, Hirokazu Takahashi, Yuya Seko, Hidenori Toyoda, Hideki Hayashi, Kanji Yamaguchi, Michihiro Iwaki and 19 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Asahiro MorishitaDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Yoshihiro KamadaDepartment of Advanced Metabolic Hepatology, Graduate School of Medicine, The University of Osaka, Osaka, Japan.
Yoshio SumidaGraduate School of Healthcare Management, International University of Healthcare and Welfare University, Tokyo, Japan.
Taeang AraiDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Hirokazu TakahashiLiver Center, Saga University Hospital, Saga, Japan.
Yuya SekoDepartment of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hidenori ToyodaDepartment of Gastroenterology and Hepatology, Ogaki Municipal Hospital, Ogaki, Japan.
Hideki HayashiDepartment of Gastroenterology and Hepatology, Gifu Municipal Hospital, Gifu, Japan.
Kanji YamaguchiDepartment of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Michihiro IwakiDepartment of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Masato YonedaDepartment of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Toshihide ShimaDepartment of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Osaka, Japan.
Hideki FujiiDepartment of Hepatology, Osaka Metropolitan University, Osaka, Japan.
Kazuhito KawataHepatology Division, Department of Internal Medicine II, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Kengo TomitaDepartment of Internal Medicine, National Defense Medical College, Tokorozawa, Japan.
Miwa KawanakaDepartment of General Internal Medicine 2, Kawasaki General Medical Center, Kawasaki Medical School, Okayama, Japan.
Yuichi YoshidaDepartment of Gastroenterology and Hepatology, Suita Municipal Hospital, Osaka, Japan.
Tadashi IkegamiDepartment of Gastroenterology and Hepatology, Tokyo Medical University Ibaraki Medical Center, Ibaraki, Japan.
Kazuo NotsumataDepartment of General Internal Medicine, Fukui-ken Saiseikai Hospital, Fukui, Japan.
Satoshi OedaLiver Center, Saga University Hospital, Saga, Japan.
Masanori AtsukawaDivision of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
Hideaki FukushimaDiagnostics Business Area, Siemens Healthcare Diagnostics K.K., Tokyo, Japan.
Hideki KobaraDepartment of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Eiji MiyoshiDepartment of Molecular Biochemistry & Clinical Investigation, Osaka University Graduate School of Medicine, Osaka, Japan.
Shinichi AishimaDepartment of Pathology and Microbiology, Faculty of Medicine, Saga University, Saga, Japan.
Takeshi OkanoueDepartment of Gastroenterology and Hepatology, Saiseikai Suita Hospital, Osaka, Japan.
Yoshito ItohDepartment of Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Atsushi NakajimaDepartment of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: The utility of the Mac-2 binding protein glycosylation isomer (M2BPGi) as a noninvasive biomarker for advanced liver fibrosis in metabolic dysfunction3associated steatotic liver disease (MASLD) is unclear. The aim of this study is to evaluate M2BPGi levels in relation to the histopathological features of MASLD and assess its diagnostic performance individually and in combination with the fibrosis-4 (FIB-4) index. Methods: A total of 992 patients with biopsy-confirmed MASLD were analyzed. Associations between the M2BPGi levels and histological features were also evaluated. Results: M2BPGi levels were significantly correlated with steatosis, lobular inflammation, ballooning, and fibrosis stages. Patients with mild steatosis (S0-1) had significantly lower M2BPGi levels than those with severe steatosis (S2-3) ( Conclusion: M2BPGi is a robust biomarker for advanced liver fibrosis in patients with MASLD. Its integration with FIB-4 in screening algorithms enhances diagnostic accuracy while minimizing unnecessary liver biopsies and specialist referrals.

Indexed as

BiomarkersFibrosis-4 IndexLiver FibrosisMetabolic Dysfunction–Associated Steatotic Liver DiseaseNoninvasive Tests

Identifiers

PMID42006192
PMCPMC13084362

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.